Join to View Full Profile
2646 E Banner Gateway DriveGilbert, AZ 85234
Phone+1 480-256-6444
Fax+1 480-256-4734
Dr. Mashni is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Corewell Health William Beaumont University HospitalResidency, Urology, 2008 - 2012- Corewell Health East Beaumont (Royal Oak)Residency, Surgery, 2006 - 2008
Loma Linda University School of MedicineClass of 2006
Certifications & Licensure
AZ State Medical License 2014 - 2028
NY State Medical License 2012 - 2027
MI State Medical License 2006 - 2012
American Board of Urology Urology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2016
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2016
Publications & Presentations
PubMed
- 4 citationsBiodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer pa...Aaron A Laviana, Elizabeth G Schiftan, Joseph W Mashni, Michael C Large, Hristos Z Kaimakliotis
Urologic Oncology. 2023-06-01 - 18 citationsAntiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of...Anirban P Mitra, Vikram M Narayan, Sharada Mokkapati, Tanner Miest, Stephen A Boorjian
European Urology. 2022-03-01 - 331 citationsIntravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella
The Lancet. Oncology. 2021-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
